Answers are grounded in this paper and cite their sources.
Experimental study demonstrates that bronchoconstrictors suppress Kv7 potassium currents in airway smooth muscle cells, indicating a novel therapeutic target for asthma.
Asthma is commonly associated with airway hyperresponsiveness (AHR) involving hypercontraction of airway smooth muscle cells (ASMCs). The mechanisms underlying this process are, however, not well understood. Here we test the hypothesis that bronchoconstrictor agonists suppress Kv7 potassium currents leading to ASMC contraction. We detected Kv7.1–7.5 mRNAs in guinea pig lung by RT‐PCR and Kv7.3–7.5 proteins by immunostaining of isolated ASMCs. Function of Kv7 channels was demonstrated in freshly isolated guinea pig ASMCs: currents measured by perforated patch whole cell voltage clamp displayed electrophysiological characteristics (slow voltage‐dependent non‐inactivating Kv currents with a very negative activation threshold (~−60mV) and a V 0.5 ~ −31 mV) and pharmacological characteristics (enhancement by selective activators, suppression by selective blockers) of Kv7 currents. Bronchoconstrictor agonists methacholine (100 nM) and histamine (30 μM), significantly suppressed Kv7 currents and this effect was reversed by Kv7 channel activators. Our results provide the first evidence that Kv7 channels are present in ASMCs, that their activity is suppressed by bronchoconstrictor agonists, and that this effect can be reversed by Kv7 channel activators. Our findings reveal novel mechanisms for ASMC hypercontraction and identify a potential new therapeutic strategy for the treatment of AHR in asthma.
No takes yet. Share an insight, caveat, or question.
Kakad et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: